Cost-Utility of Idelalisib In Combination with Rituximab In Relapsed or Refractory Chronic Lymphocytic Leukemia
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.898
https://www.valueinhealthjournal.com/article/S1098-3015(17)31232-9/fulltext
Title :
Cost-Utility of Idelalisib In Combination with Rituximab In Relapsed or Refractory Chronic Lymphocytic Leukemia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31232-9&doi=10.1016/j.jval.2017.08.898
First page :
A557
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
857